JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online May 15, 2008, 10.2967/jnumed.107.048207
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
jnumed.107.048207v1
49/6/931    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by O'Brien, T. J.
Right arrow Articles by Hicks, R. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Brien, T. J.
Right arrow Articles by Hicks, R. J.
Journal of Nuclear Medicine Vol. 49 No. 6 931-937
© 2008 by Society of Nuclear Medicine
doi: 10.2967/jnumed.107.048207

Clinical Investigation

The Cost-Effective Use of 18F-FDG PET in the Presurgical Evaluation of Medically Refractory Focal Epilepsy

Terence J. O'Brien1, Ken Miles2, Robert Ware3, Mark J. Cook4, David S. Binns3 and Rodney J. Hicks3

1 Departments of Medicine, Surgery, and Neurology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia; 2 Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom; 3 Centre for Molecular Imaging, Peter MacCallum Cancer Institute, Victoria, Australia; and 4 Centre for Clinical Neuroscience and Neurological Research, St. Vincent's Hospital, Melbourne, Australia

Correspondence: For correspondence or reprints contact: Terence J. O'Brien, Department of Medicine, Royal Melbourne Hospital, Royal Parade, Parkville 3050, Victoria, Australia. E-mail: obrientj{at}unimelb.edu.au

This study applied decision tree analysis to evaluate the sensitivity, specificity, and cost-effectiveness of clinical algorithms that incorporate 18F-FDG PET. Methods: A cohort of 176 patients was studied. The localization rate, accuracy, therapeutic impact on the presurgical decision-making process, and correlation with the postsurgical outcome were assessed for the tests commonly performed for seizure localization. Decision tree sensitivity analysis compared 3 imaging strategies with a baseline strategy of medical therapy for all: video-electroencephalography monitoring (VEM)/MRI strategy, in which patients underwent VEM and brain MRI only, and +SPECT and +PET strategies, in which patients with an indeterminate VEM/MRI result underwent ictal SPECT or interictal 18F-FDG PET, respectively. Results: The localization rates for VEM, MRI, 18F-FDG PET, ictal SPECT, and intracranial electroencephalography (EEG) were 62.2%, 35.8%, 75.0%, 60.0%, and 93.8%. The VEM/MRI strategy had the lowest cost per class I/II outcome, but the additional costs per class I/II outcome for the +PET and +SPECT strategies were always below the minimum reported cost savings for a class I/II outcome. There were no valid conditions in which the +SPECT strategy had a lower cost per class I/II outcome than the +PET strategy. Within the range of cost savings estimated to be associated with a class I/II outcome, all decision strategies produced net cost savings; however, these were significantly higher for the +PET and the +SPECT strategies. Conclusion: 18F-FDG PET is cost-effective in the presurgical evaluation, particularly when used in patients with a nonlocalizing or nonconcordant VEM or MRI result.

Key Words: neurology • PET • decision tree analysis • epilepsy • epilepsy surgery • FDG • PET

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2008 49: 13A-14A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.